KRS July Final Jour.09. - Association of Biotechnology and Pharmacy
KRS July Final Jour.09. - Association of Biotechnology and Pharmacy
KRS July Final Jour.09. - Association of Biotechnology and Pharmacy
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Current Trends in <strong>Biotechnology</strong> <strong>and</strong> <strong>Pharmacy</strong><br />
Vol. 3 (3) 225 - 240, <strong>July</strong> 2009. ISSN 0973-8916<br />
Acknowledgements<br />
Authors are thankful to the National<br />
Academy <strong>of</strong> Sciences, <strong>and</strong> other web sites for<br />
providing the valuable information on intellectual<br />
property rights <strong>and</strong> research tools in molecular<br />
biology. Most part <strong>of</strong> the text in this review has<br />
the information taken from many source other<br />
than scientific journals, which were not cited or<br />
referenced.<br />
References<br />
1. Pisano, G.P. (2006) Can science be a business<br />
Lessons from biotech. Harv Bus Rev.<br />
84(10):114-24, 150.<br />
2. Bayh-Dole Act 35 USC §§ 200-212 (1980).<br />
3. Rudolph, L. (1994) Overview <strong>of</strong> Federal<br />
Technology Transfer. Risk. Health, Safety<br />
& Environment 5: 133-142.<br />
4. Belcher, M <strong>and</strong> A.G. Sheard. (1993)<br />
Pr<strong>of</strong>iting from inventions in academia:<br />
American <strong>and</strong> British perspectives.<br />
Ann.Clin.Biochem.30:1-10.<br />
5. Pub. Law No. 96-517, 6(a), 94 Stat. 3015,<br />
3019-27 (1980).<br />
6. Pub. Law No. 96-480, 94 Stat. 2311 (1980).<br />
7. US Patent Law 333 US 127 (1948).<br />
8. US Patent Law 447 US 303 (1980).<br />
9. Ex parte Hibberd. 227 USPQ2d (BNA) 443<br />
(Pat. Off. Bd. App. 1985).<br />
10. Ex parte Allen. 2 USPQ2d (BNA) 1425<br />
(Bd. Pat. App. & Int. 1987).<br />
240<br />
11. US PTO, Commissioner’s Notice, Official<br />
Gazette <strong>of</strong> the Patent <strong>and</strong> Trademark Office<br />
1077:24, (1987).<br />
12. Amended at 35 USC §§ 200-211, 301-307<br />
<strong>and</strong> at 15 USC §§ 3701-3714.<br />
13. Yablonsky, M.D <strong>and</strong> W.J.Hone. (1995)<br />
Patenting DNA sequences. <strong>Biotechnology</strong><br />
13:656-657.<br />
14. Eckenswiller, C <strong>and</strong> J.Morrow. (1996)<br />
Why patent life forms Policy options<br />
17:11-15.<br />
15. Crespi, R.S (1997) <strong>Biotechnology</strong> patents<br />
<strong>and</strong> morality. Trends Biotechnol.15:123-<br />
129.<br />
16. 29 F. Cas. 1120 (C.C.D. Mass. 1813) (No.<br />
17,600).<br />
17. 733 F.2d 858 (Fed. Cir.), cert. denied, 469<br />
US 856 (1984).<br />
18. Drug Price Competition <strong>and</strong> Patent Term<br />
Restoration Act <strong>of</strong> 1984, Public Law 98-<br />
417, codified in pertinent part at 35 USC §<br />
271(e) (1984).<br />
19. Beardsley T. (1994) Big time biology.<br />
Scientific American. : 90-97.<br />
20. Saiki, R.K. Scharf, S., Faloona, F., Mullis,<br />
K.B., Horn, G.T., Erlich, H.A <strong>and</strong> Arnheim,<br />
N. (1985)Enzymatic amplification <strong>of</strong> betaglobin<br />
genomic sequences <strong>and</strong> restriction<br />
site analysis for diagnosis <strong>of</strong> sickle cell<br />
anemia. Science 230(4732):1350-4.<br />
Firoz et al